• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy.抗体依赖的细胞细胞毒性在单克隆抗体介导的肿瘤免疫治疗中的作用。
Oncoimmunology. 2012 Jan 1;1(1):103-105. doi: 10.4161/onci.1.1.17963.
2
Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.在肿瘤特异性抗体免疫治疗期间，抗体依赖的细胞细胞毒性突触在小鼠中形成。
Cancer Res. 2011 Aug 1;71(15):5134-43. doi: 10.1158/0008-5472.CAN-10-4222. Epub 2011 Jun 22.
3
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.NK 细胞的抗肿瘤作用和抗 PD-L1 抗体的抗体依赖性细胞细胞毒性在 PD-L1 阳性癌细胞系中的作用。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000873.
4
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.重组白细胞介素2体内治疗后抗体依赖性细胞介导的细胞毒性增强。
Cancer Res. 1990 Sep 1;50(17):5234-9.
5
A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.一种针对铰链区裂解的IgG的单克隆抗体在体外和体内均可恢复经蛋白水解失活的IgG的效应器功能。
MAbs. 2014;6(5):1265-73. doi: 10.4161/mabs.29825. Epub 2014 Oct 30.
6
A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.通过抗体依赖性细胞介导的细胞毒性作用，利用 NK 或高亲和力 NK 细胞联合西妥昔单抗治疗软骨肉瘤的一种潜在疗法。
J Neurosurg. 2018 May;128(5):1419-1427. doi: 10.3171/2017.1.JNS162610. Epub 2017 Jul 28.
7
[Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].抗体依赖细胞介导的细胞毒性抗肿瘤作用的研究进展——综述
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1370-5.
8
Myeloid cells as effector cells for monoclonal antibody therapy of cancer.髓系细胞作为单克隆抗体治疗癌症的效应细胞。
Methods. 2014 Jan 1;65(1):28-37. doi: 10.1016/j.ymeth.2013.06.020. Epub 2013 Jun 27.
9
Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.去岩藻糖基化抗CCR4单克隆抗体在NOD/Shi-scid、IL-2Rγ（缺失）小鼠体内对由自体人类免疫细胞介导的原发性成人T细胞白血病/淋巴瘤（ATLL）细胞发挥强大的抗体依赖的细胞介导的细胞毒性作用（ADCC）。
J Immunol. 2009 Oct 1;183(7):4782-91. doi: 10.4049/jimmunol.0900699. Epub 2009 Sep 11.
10
Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.单克隆抗体D612增强淋巴因子激活的杀伤细胞对人结肠癌的细胞毒性。
Int J Cancer. 1990 Dec 15;46(6):1021-8. doi: 10.1002/ijc.2910460613.

引用本文的文献

1
Therapeutic antibodies in oncology: an immunopharmacological overview.肿瘤学中的治疗性抗体：免疫药理学概述。
Cancer Immunol Immunother. 2024 Oct 3;73(12):242. doi: 10.1007/s00262-024-03814-2.
2
Cancer immunotherapy and its facilitation by nanomedicine.癌症免疫疗法及其纳米医学促进作用。
Biomark Res. 2024 Aug 3;12(1):77. doi: 10.1186/s40364-024-00625-6.
3
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives.用于精准癌症免疫治疗的治疗性抗体：现状与未来展望
Med Rev (2021). 2023 Jan 16;2(6):555-569. doi: 10.1515/mr-2022-0033. eCollection 2022 Dec.
4
3D bioprinted cancer models: from basic biology to drug development.3D生物打印癌症模型：从基础生物学到药物开发
Nat Rev Cancer. 2022 Dec;22(12):679-692. doi: 10.1038/s41568-022-00514-w. Epub 2022 Oct 24.
5
Adverse Renal Effects of Anticancer Immunotherapy: A Review.抗癌免疫疗法的肾脏不良反应：综述
Cancers (Basel). 2022 Aug 23;14(17):4086. doi: 10.3390/cancers14174086.
6
Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.用于华氏巨球蛋白血症的单克隆抗体疗法。
Leuk Res Rep. 2022 May 6;17:100324. doi: 10.1016/j.lrr.2022.100324. eCollection 2022.
7
Trial watch: intratumoral immunotherapy.试验观察：肿瘤内免疫疗法。
Oncoimmunology. 2021 Oct 15;10(1):1984677. doi: 10.1080/2162402X.2021.1984677. eCollection 2021.
8
Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.用抗 CD38 单克隆抗体对同种异体人自然杀伤细胞进行选择、扩增和独特预处理，以有效治疗多发性骨髓瘤。
Cells. 2021 Apr 21;10(5):967. doi: 10.3390/cells10050967.
9
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.试验观察：用于肿瘤适应症的肿瘤靶向单克隆抗体
Oncoimmunology. 2015 Feb 3;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.
10
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.基于肿瘤抗原靶向单克隆抗体的免疫治疗：为长期抗肿瘤免疫的发展协调联合策略。
Oncoimmunology. 2014 Dec 13;3(9):e955684. doi: 10.4161/21624011.2014.955684. eCollection 2014 Oct.

本文引用的文献

1
Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.在肿瘤特异性抗体免疫治疗期间，抗体依赖的细胞细胞毒性突触在小鼠中形成。
Cancer Res. 2011 Aug 1;71(15):5134-43. doi: 10.1158/0008-5472.CAN-10-4222. Epub 2011 Jun 22.
2
Immune parameters affecting the efficacy of chemotherapeutic regimens.影响化疗方案疗效的免疫参数。
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. doi: 10.1038/nrclinonc.2010.223.
3
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.I 型 CD20 抗体的体内细胞毒性严重依赖于 Fc 受体 ITAM 信号传导。
Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30.
4
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.小鼠CD20免疫疗法期间的淋巴瘤耗竭由巨噬细胞FcγRI、FcγRIII和FcγRIV介导。
Blood. 2008 Aug 15;112(4):1205-13. doi: 10.1182/blood-2008-01-135160. Epub 2008 May 21.
5
Monoclonal antibody therapy of cancer.癌症的单克隆抗体疗法。
Nat Biotechnol. 2005 Sep;23(9):1147-57. doi: 10.1038/nbt1137.
6
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.人源化抗CD20单克隆抗体的治疗活性及IgG Fc受体FcγRIIIa基因多态性
Blood. 2002 Feb 1;99(3):754-8. doi: 10.1182/blood.v99.3.754.
7
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.抑制性Fc受体调节体内对肿瘤靶标的细胞毒性。
Nat Med. 2000 Apr;6(4):443-6. doi: 10.1038/74704.
8
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.环磷酰胺诱导的旁观者效应在小鼠过继性免疫治疗中对成功根除肿瘤的T细胞的重要性。
J Clin Invest. 1998 Jan 15;101(2):429-41. doi: 10.1172/JCI1348.
9
T and Tn, general carcinoma autoantigens.T和Tn，一般的癌自身抗原。
Science. 1984 Jun 15;224(4654):1198-206. doi: 10.1126/science.6729450.
10
Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate.使用合成肿瘤相关糖缀合物对小鼠乳腺腺癌进行主动特异性免疫治疗。
Cancer Res. 1990 Jul 15;50(14):4308-14.

抗体依赖的细胞细胞毒性在单克隆抗体介导的肿瘤免疫治疗中的作用。

Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy.

机构信息

Institut Curie; Centre de Recherche; Paris, France ; INSERM; U93; Paris, France.

出版信息

Oncoimmunology. 2012 Jan 1;1(1):103-105. doi: 10.4161/onci.1.1.17963.

DOI:10.4161/onci.1.1.17963
PMID:22720225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3376972/
Abstract

Antibody-dependent cell cytotoxicity (ADCC) is critical in monoclonal antibody (mAb)-mediated cancer therapy. We recently showed that a tumor-specific mAb in combination with cyclophosphamide inhibited tumor cell growth and induced ADCC-synapses between tumor and effector cells in vivo, opening perspectives to enhance anti-tumor responses by manipulating the immune system.

摘要

抗体依赖的细胞细胞毒性 (ADCC) 在单克隆抗体 (mAb) 介导的癌症治疗中至关重要。我们最近表明，一种肿瘤特异性 mAb 与环磷酰胺联合使用可以抑制肿瘤细胞生长，并在体内诱导肿瘤和效应细胞之间的 ADCC 突触，为通过操纵免疫系统增强抗肿瘤反应开辟了前景。